
Core Insights - Foresight Autonomous Holdings Ltd. reported financial results for Q2 and the first half of 2025, highlighting progress in commercial agreements and technological advancements in 3D perception systems [1][4][6]. Second Quarter Corporate Highlights - Revenues for Q2 2025 were $128,000, a slight increase from $123,000 in Q2 2024, primarily driven by agreements with Elbit Systems and successful testing with Software République [6]. - The company signed a $12 million commercialization agreement with Zhejiang StreamRail for urban rail transit integration, with expected deployment in 2026 [7]. - A collaboration with a Tier-One automotive supplier aims to enhance bus safety using Foresight's technology, with proof-of-concept testing ongoing in H2 2025 [7]. First Half 2025 Corporate Highlights - Total revenues for the first half of 2025 reached $240,000, compared to $224,000 in the same period of 2024 [9]. - Research and development expenses decreased by 2.2% to $4,426,000, while sales and marketing expenses increased by 9.2% to $629,000 [9]. - General and administrative expenses rose by 11.6% to $1,296,000, mainly due to increased share-based compensation [9]. Financial Performance - GAAP net loss for Q2 2025 was $2,815,000, improving from a loss of $3,172,000 in Q2 2024 [9]. - Non-GAAP net loss for Q2 2025 was $2,598,000, compared to $3,030,000 in Q2 2024 [10]. - For the first half of 2025, GAAP net loss was $6,095,000, compared to $4,708,000 in the first half of 2024 [10]. Balance Sheet Highlights - As of June 30, 2025, cash and cash equivalents totaled $6,392,000, down from $7,182,000 at the end of 2024 [18]. - Total equity decreased by 16.4% to $5,625,000, primarily due to the net loss for the period [18]. Technological Developments - Foresight enhanced its perception systems by integrating NVIDIA Jetson Orin platforms, significantly improving AI processing capabilities for automotive and drone applications [7]. - Eye-Net Mobile made significant strides in V2X safety, completing a paid proof-of-concept with a major European OEM and achieving successful trial results in France [5].